SYNDAX PHARMACEUTICALS INC SNDX
ASignal's systematic analysis rates SNDX as Bearish.
Reflects the latest available analysis · analyzed Nov 3, 2026
The case on SNDX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (91.8% YoY)
- High cash position relative to debt (current ratio 6.77x)
- Positive free cash flow trend relative to peers in biotech
- Recent MACD histogram improvement suggesting weakening bearish momentum
- Negative operating and gross margins
- Negative return on equity and assets
- Overvalued on EV/EBITDA (-6.21x) and P/B (17.73x)
- Bearish price momentum with price below SMA20 and SMA50
- Low news diversity with only two sources (Yahoo, SeekingAlpha)
See the full verdict on SNDX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SNDX
Most investors never get a second opinion, let alone several. ASignal runs SNDX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.